Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
investigational drug recombinant human growth hormone |
| gptkbp:affects |
gptkb:prolactin
glucose metabolism cortisol body composition insulin-like growth factor 1 (IGF-1) growth hormone (GH) |
| gptkbp:alsoKnownAs |
gptkb:Ibutamoren
|
| gptkbp:ATCCode |
none
|
| gptkbp:bioavailability |
oral, high
|
| gptkbp:CASNumber |
159752-10-0
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:compatibleWith |
gptkb:SARM
anabolic steroid controlled substance (US) |
| gptkbp:developedBy |
Reverse Pharmacology
|
| gptkbp:discoveredBy |
1990s
|
| gptkbp:eliminationHalfLife |
24 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C27H36N4O5S
|
| https://www.w3.org/2000/01/rdf-schema#label |
MK-677
|
| gptkbp:KEGGID |
D10868
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
stimulates growth hormone release
ghrelin receptor agonist |
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
528.66 g/mol
|
| gptkbp:not_approved_by |
gptkb:FDA
gptkb:EMA |
| gptkbp:PubChem_CID |
140375
159632 CHEMBL1214128 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
muscle pain
increased appetite mild edema transient increase in cortisol |
| gptkbp:structure |
amide group
thiazole ring benzyl group nitrile group |
| gptkbp:UNII |
QX8X9C6UFZ
|
| gptkbp:usedFor |
potential treatment of growth hormone deficiency
potential treatment of muscle wasting potential treatment of obesity potential treatment of osteoporosis |
| gptkbp:bfsParent |
gptkb:151096-09-2
gptkb:170729-80-3 |
| gptkbp:bfsLayer |
6
|